The companies have previously told the court that their COVID vaccine Comirnaty does not work in the same way as CureVac's patented technology. In 2010, TransData initiated patent infringement lawsuits against a number of companies alleging the unlawful use of TransData’s patented technology inside their digital electric meters. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. The financial terms of the licensing agreement, which includes TransData’s U.S. Pfizer and BioNTech in response had filed a complaint with the U.S. Pfizer and BioNTech did not immediately respond to requests for comment. The 294 Patent is the subject matter of patent infringement lawsuits TransData filed against a group of electric utilities involving millions of digital electric meters equipped with internal wireless communications that are commonly referred to as 'smart meters.' The case is currently pending before the U.S.
Transdata patent lawsuit trial#
The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine. If you continue using our website, well assume that you are happy to receive all cookies on this website. We use them to give you the best experience. The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. TransData’s Smart Electric Meter Patents cover pioneering technology invented by TransData that enables equipping a digital electric meter with an internal.
court had granted its request to transfer the trial.
May 19 (Reuters) - CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc (PFE.N) and BioNTech over the use of mRNA technology and that a U.S. 16, 2015 /PRNewswire/ - TransData, Inc.
0 kommentar(er)
